Premium
Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease”
Author(s) -
Siemers Eric R.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.03.017
Subject(s) - disease , clinical trial , medicine , clinical study design , psychology
In this issue of Alzheimer’s & Dementia , Mohs et al [1] rovide a summary of a conference held by the Alzheimer’s ssociation Research Roundtable to discuss appropriate rial designs for drugs intended to slow the rate of decline in lzheimer’s disease (AD). The discussants included experts n AD trial design and also experts in the fields of multiple clerosis (MS), rheumatoid arthritis (RA), osteoporosis, and ardiovascular disease. By bringing these individuals toether, concepts from other disease states could be considred as possibly applying to research in AD. The timeliness of this meeting was emphasized by brief resentations regarding 4 treatments, now in clinical develpment, which may slow AD progression. A monoclonal ntibody, AB001, and a -secretase inhibitor, LY450139, re being studied in Phase 2 trials. An agent that binds A , lzhemed, and an allosteric modulator of -secretase, Rlurbiporfen, are now in Phase 3 trials. Although these rugs are intended to slow the rate of progression of AD, a lear consensus on the evidence necessary to show such an ffect has not yet been achieved. Thus, a meeting such as his one is of critical importance.